JP7490569B2 - キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 - Google Patents

キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 Download PDF

Info

Publication number
JP7490569B2
JP7490569B2 JP2020559371A JP2020559371A JP7490569B2 JP 7490569 B2 JP7490569 B2 JP 7490569B2 JP 2020559371 A JP2020559371 A JP 2020559371A JP 2020559371 A JP2020559371 A JP 2020559371A JP 7490569 B2 JP7490569 B2 JP 7490569B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
cycloalkyl
cancer
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522238A (ja
JP2021522238A5 (enExample
Inventor
ワン，トン
ゲイトリー，スティーヴン
Original Assignee
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー filed Critical トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー
Publication of JP2021522238A publication Critical patent/JP2021522238A/ja
Publication of JP2021522238A5 publication Critical patent/JP2021522238A5/ja
Application granted granted Critical
Publication of JP7490569B2 publication Critical patent/JP7490569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2020559371A 2018-04-24 2019-04-24 キナーゼ阻害剤としてのアミド化合物、組成物および処置方法 Active JP7490569B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862662105P 2018-04-24 2018-04-24
US62/662,105 2018-04-24
US201962788461P 2019-01-04 2019-01-04
US62/788,461 2019-01-04
PCT/US2019/029003 WO2019210008A1 (en) 2018-04-24 2019-04-24 Amide compounds as kinase inhibitors, compositions and methods of treatment

Publications (3)

Publication Number Publication Date
JP2021522238A JP2021522238A (ja) 2021-08-30
JP2021522238A5 JP2021522238A5 (enExample) 2022-04-21
JP7490569B2 true JP7490569B2 (ja) 2024-05-27

Family

ID=68294245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559371A Active JP7490569B2 (ja) 2018-04-24 2019-04-24 キナーゼ阻害剤としてのアミド化合物、組成物および処置方法

Country Status (7)

Country Link
US (2) US11555039B2 (enExample)
EP (1) EP3784226B1 (enExample)
JP (1) JP7490569B2 (enExample)
CN (1) CN112367982B (enExample)
CA (1) CA3097638A1 (enExample)
IL (1) IL278194B2 (enExample)
WO (1) WO2019210008A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2025135087A1 (ja) * 2023-12-19 2025-06-26 株式会社デ・ウエスタン・セラピテクス研究所 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536925A (ja) 2007-08-27 2010-12-02 アボット ゲーエムベーハー ウント カンパニー カーゲー ４−（４−ピリジニル）−ベンズアミドおよびｒｏｃｋ活性調節因子としてのこれらの使用
JP2013531013A (ja) 2010-07-07 2013-08-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＲｈｏキナーゼインヒビターとしてのＮ−環式−３−（環状カルボニルアミノメチル）ベンズアミド誘導体
JP2016510032A (ja) 2013-02-28 2016-04-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
WO2016187324A1 (en) 2015-05-18 2016-11-24 Td2, Inc. Heterocyclic compounds as kinase inhibitors
JP6948398B2 (ja) 2016-10-24 2021-10-13 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
EP1854484A4 (en) * 2005-02-16 2010-02-10 Astellas Pharma Inc REMEDY FOR PAIN CONTAINING INHIBITOR OF RHO-KINASE PROTEIN
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536925A (ja) 2007-08-27 2010-12-02 アボット ゲーエムベーハー ウント カンパニー カーゲー ４−（４−ピリジニル）−ベンズアミドおよびｒｏｃｋ活性調節因子としてのこれらの使用
JP2013531013A (ja) 2010-07-07 2013-08-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＲｈｏキナーゼインヒビターとしてのＮ−環式−３−（環状カルボニルアミノメチル）ベンズアミド誘導体
JP2016510032A (ja) 2013-02-28 2016-04-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
WO2016187324A1 (en) 2015-05-18 2016-11-24 Td2, Inc. Heterocyclic compounds as kinase inhibitors
JP6948398B2 (ja) 2016-10-24 2021-10-13 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物

Also Published As

Publication number Publication date
WO2019210008A1 (en) 2019-10-31
EP3784226A1 (en) 2021-03-03
EP3784226B1 (en) 2024-08-14
US20210047335A1 (en) 2021-02-18
US20230143583A1 (en) 2023-05-11
JP2021522238A (ja) 2021-08-30
CA3097638A1 (en) 2019-10-31
CN112367982A (zh) 2021-02-12
IL278194B2 (en) 2023-12-01
IL278194A (enExample) 2020-12-31
EP3784226A4 (en) 2022-01-26
IL278194B1 (en) 2023-08-01
CN112367982B (zh) 2024-05-07
US11555039B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
EP3532479B1 (en) Amide compounds as kinase inhibitors
JP7335893B2 (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのクロメノピリジン誘導体
EP3555066A1 (en) Benzimidazole compounds as c-kit inhibitors
EP3555090A1 (en) Aminothiazole compounds as c-kit inhibitors
CA2952692A1 (en) Substituted imidazo[1,2b]pyridazine compounds
US10738007B2 (en) Amide compounds as kinase inhibitors, compositions and methods of treatment
JP2024535867A (ja) 治療薬としてｎ－アリールピリミジン－２－アミン誘導体を有する化合物
EP3784226B1 (en) Pyrazole-phenylamide derivatives as inhibitors of the rho-associated protein kinase rock1 and rock2 for the treatment of cancer
AU2022206787C1 (en) Amide compounds as kinase inhibitors, compositions and methods of treatment
JP2024539633A (ja) 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用
HK40081274A (en) Amide compounds as kinase inhibitors
HK40046916A (en) Amide compounds as kinase inhibitors, compositions and methods of treatment
HK40046916B (zh) 作为激酶抑制剂的酰胺化合物、组合物和治疗方法
HK40010105A (en) Amide compounds as kinase inhibitors
HK40010105B (en) Amide compounds as kinase inhibitors
HK40039568B (en) Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
HK40039568A (en) Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220413

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240515

R150 Certificate of patent or registration of utility model

Ref document number: 7490569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150